ARTICLE | Company News
Potentia, Alcon deal
October 26, 2009 7:00 AM UTC
Alcon's Alcon Research Ltd. subsidiary received exclusive, worldwide rights to Potentia's POT-4 and an option to acquire the biotech. The synthetic peptide C3 inhibitor has completed a Phase I trial ...